

# Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)  
Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294  
Factory : Plot No. B-4 & 5, Industrial Focal Point, Derabassi, Punjab (India)  
Ph. 01762-281278, 79. CIN NO. U74999CH1993PLC033428

Date: 12<sup>th</sup> December, 2017

The President,  
Corporate Relationship Department,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

**BSE Scrip Code: 524652**

The Vice President,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051

**NSE Symbol: INDSWFTLTD**

**Ref: Company Name: Ind-Swift Limited**

**Sub: Disclosures under Regulations 10(6) and 29 (2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011**

Dear Sir,

This is to inform the Exchange that pursuant to the Composite scheme of amalgamation inter-alia of AKJ Portfolios Pvt Ltd., GM Portfolios Pvt. Ltd., NRM Portfolios Pvt. Ltd., SRM Portfolios Pvt. Ltd., VKM Portfolios Pvt. Ltd. and VRM Portfolios Pvt. Ltd. ("Transferor Companies") with Essix Biosciences Limited ("Transferee Company") as approved by Hon'ble National Company Law Tribunal, Chandigarh Bench vide its order CP No. 153/2016 dated 08.11.2017, received on 06.12.2017, the transferor Companies have been amalgamated with the transferee Company with effect from 09.12.2017. Pursuant to the sanctioned scheme, the entire shareholding of Ind-Swift Limited held by the Transferor Companies stands transferred to the transferee Company.


In this regard, please find enclosed the following:

- (i) Report under Regulation 10(6) of the SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011
- (ii) Disclosure under Regulation 29(2) of the SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011

You are requested to kindly take the same on record.

For Essix Biosciences Limited

  
Director




Cc:

The Compliance Officer  
Ind-Swift Limited  
781, INDUSTRIAL AREA,  
PHASE-II, CHANDIGARH-160002

**Format for Disclosures under Regulation 10(6) – Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**


1.	Name of the Target Company (TC)	Ind-Swift Limited	
2.	Name of the acquirer(s)	Essix Biosciences Limited	
3.	Name of the stock exchange where shares of the TC are listed	BSE Ltd. and National Stock Exchange of India Limited	
4.	Details of the transaction including rationale, if any, for the transfer/acquisition of shares.	<p>Pursuant to a composite scheme of amalgamation of AKJ Portfolios Pvt Ltd., GM Portfolios Pvt. Ltd., NRM Portfolios Pvt. Ltd., SRM Portfolios Pvt. Ltd., VKM Portfolios Pvt. Ltd., VRM Portfolios Pvt. Ltd., Integral Buildcon Private Limited and Consummate Pharmaceuticals Pvt. Ltd. (“<b>Transferor Companies</b>”) with Essix Biosciences Limited (“<b>Transferee Company</b>”) as approved by Hon’ble National Company Law Tribunal, Chandigarh Bench vide its order CP No. 153/2016 dated 08.11.2017, received on 06.12.2017, the transferor Companies stand amalgamated with the transferee Company with effect from 09.12.2017, and consequently, all the assets and liabilities of the Transferor Companies including their shareholding in Ind-Swift Limited (i.e. the target Company) stand transferred to the transferee Company.</p> <p>Accordingly, 7817712 equity shares of Ind-Swift Limited constituting 14.45% of the paid up share capital of Ind-Swift Limited as held by transferor Companies stand transferred to the Transferee Company (subject to completion of requisite procedural formalities) in addition to existing shareholding of transferee Company in Ind-Swift Ltd of 9215721 equity shares.</p> <p>The key rationale for the amalgamation envisaged under the scheme is that the amalgamation shall provide the Transferee Company a strong and focused base to undertake the business more advantageously. The scheme will also result in the consolidation of the Promoter shareholding in Ind-Swift Limited and the consolidation of group Companies.</p>	
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10(1)(d)(iii) of SEBI(Substantial Acquisition of Shares and Takeover) Regulations, 2011. (SAST Regulations)	
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, – Whether disclosure was made and whether it was made within the timeline specified under the regulations. – Date of filing with the stock exchange.	<p>The disclosure under Regulation 10(5) of the SAST Regulations is not required to be made in the present case.</p> <p>N.A.</p> <p>N.A.</p>	
7.	Details of acquisition	Disclosures made/required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made



	a. Name of the transferor / seller	N.A.		N.A.	
	b. Date of acquisition	N.A.		N.A.	
	c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	N.A.		N.A.	
	d. Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	N.A.		N.A.	
	e. Price at which shares are proposed to be acquired / actually acquired	N.A.		N.A.	
8.	Shareholding details	Pre-Transaction		Post-Transaction	
		No. of shares held	% w.r.t. to total share capital of TC	No. of shares held	% w.r.t. to total share capital of TC
	- Each Acquirer-/ Transferee(*)				
	Essix Biosciences Limited	9215721	17.01	17033433	31.45
	- Each Seller-/ Transferor				
	AKJ Portfolios Pvt. Limited	675000	1.25	-	-
	NRM Portfolios Pvt. Limited	675000	1.25	-	-
	GM Portfolios Pvt. Limited	2675000	4.94	-	-
	VKM Portfolios Pvt. Limited	650000	1.20	-	-
	VRM Portfolios Pvt. Limited	1303570	2.41	-	-
	SRM Portfolios Pvt. Limited	1839142	3.40	-	-

For ESSIX BIOSCIENCES LIMITED

  
**V.R. MEHTA**  
 DIRECTOR  
 DIN: 00010756



Place: Chandigarh  
 Date: 12.12.2017

- Note:
- (\*) Shareholding of each entity shall be shown separately and then collectively in a group.
  - The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.